Strategic Insights for Launching Acute Ischemic Stroke Treatments in the US, UK, and Germany

CHALLENGE

A strategy consulting firm's client aimed to introduce a new drug for acute ischemic stroke into the US, UK, and German markets. To achieve this, they needed to thoroughly understand the landscape of market access and reimbursement policies in these regions. The client's objective was to gather comprehensive insights into the regulatory requirements, pricing strategies, and the healthcare systems' receptivity to new stroke treatments. Moreover, they sought to engage with experienced industry professionals who had previously navigated similar challenges, as well as former payers involved in drug pricing process.

BTHT APPROACH

Our team undertook a focused approach to identify and connect with a diverse range of experts from the pharmaceutical industry and healthcare systems in the US, UK, and Germany. Our team successfully sourced and engaged with: - Former Private & Public Payers that had experience in pricing negotiations and reimbursement processes within their respective healthcare systems, offering valuable insights into the economic aspects of market access. - Industry Experts including a former National Account Director, a former Head of Market Access, and a former Director of Public Policy, who had previously managed the launch of drugs for acute ischemic stroke. These individuals provided detailed knowledge about regulatory pathways, market dynamics, and strategic considerations.

BTHT team facilitated the 1 hour interviews as usual to make sure the process went through smoothly.

OUTCOME

The consulting firm received critical insights into the various aspects of market access, including the regulatory environment, reimbursement strategies, and clinical considerations for acute ischemic stroke drugs in the US, UK, and Germany. The detailed feedback from former payers and industry experts, equipped the client with a robust foundation to advise their client. This knowledge was pivotal in developing a strategic plan for the drug's market entry and positioning, ensuring alignment with the specific needs and expectations of each regional market.